Ropes Wealth Advisors LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,731 shares of the biopharmaceutical company’s stock after buying an additional 2,836 shares during the period. Ropes Wealth Advisors LLC’s holdings in Gilead Sciences were worth $661,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Abner Herrman & Brock LLC raised its stake in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. Blue Fin Capital Inc. raised its stake in Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 55 shares during the last quarter. Barrington Strategic Wealth Management Group LLC raised its stake in Gilead Sciences by 0.9% in the fourth quarter. Barrington Strategic Wealth Management Group LLC now owns 7,933 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 67 shares during the last quarter. Searle & CO. raised its stake in Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 80 shares during the last quarter. Finally, Alpha Windward LLC raised its stake in Gilead Sciences by 2.4% in the first quarter. Alpha Windward LLC now owns 3,921 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 92 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (GILD) opened at 73.76 on Friday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85. The company has a 50-day moving average price of $68.32 and a 200-day moving average price of $68.63. The firm has a market capitalization of $96.38 billion, a price-to-earnings ratio of 7.80 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.18 by $0.02. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Equities analysts forecast that Gilead Sciences, Inc. will post $8.41 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Stockholders of record on Friday, June 16th were paid a $0.52 dividend. The ex-dividend date was Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 21.99%.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/23/ropes-wealth-advisors-llc-purchases-2836-shares-of-gilead-sciences-inc-nasdaqgild.html.

Several analysts have weighed in on GILD shares. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 target price for the company in a research note on Tuesday, April 18th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. J P Morgan Chase & Co restated an “overweight” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a research report on Tuesday, May 2nd. Finally, Barclays PLC restated an “overweight” rating and set a $85.00 price target (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.09.

In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Francis Cogan sold 9,943 shares of the stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. In the last three months, insiders sold 88,276 shares of company stock valued at $6,230,610. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.